AnaptysBio Inc. Insider Trading

ANAB

Last 12 months

Insiders sold $9.75M and bought nothing on the open market.

37% of the selling was scheduled in advance under 10b5-1 plans. Director John P. Schmid sold $1.16M on Mar 30, 39% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2021.

Net open-market

−$9.75M

0 buys · 23 sales

Under a 10b5-1 plan

37%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

May 2021

May 4, 2021

Get an email when ANAB's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 1	Hollings Renton Director	Sold10b5-1 plan	5,000	$49.87	249K	31%	Form 4
Mar 30	John P. Schmid Director	SoldNo plan 3 parts	20,645	$56.11 average	$1.16M	39%	Form 4
Mar 27	Daniel Faga President, CEO	SoldNo plan 10 parts	17,679	$61.61 average	$1.09M	3.4%	Form 4
Feb 11	Eric J Loumeau Chief Legal Officer	Sold10b5-1 plan	10,000	$54.00	540K	44%	Form 4
Jan 15	Magda Marquet Director	SoldNo plan 2 parts	11,000	$48.23 average	531K	53%	Form 4
Jan 8	Paul F. Lizzul Chief Medical Officer	SoldNo plan	3,650	$44.71	163K	8.0%	Form 4
Jan 8	Daniel Faga President, CEO	SoldNo plan	14,281	$44.71	639K	2.9%	Form 4
Jan 8	Dennis Mulroy Chief Financial Officer	SoldNo plan	2,515	$44.71	112K	10%	Form 4
Jan 8	Eric J Loumeau Chief Legal Officer	SoldNo plan	2,210	$44.71	99K	15%	Form 4
Jan 7	Paul F. Lizzul Chief Medical Officer	SoldNo plan	2,235	$45.11	101K	5.7%	Form 4
Jan 7	Daniel Faga President, CEO	SoldNo plan	9,202	$45.11	415K	1.9%	Form 4
Jan 7	Dennis Mulroy Chief Financial Officer	SoldNo plan	1,908	$45.11	86K	9.7%	Form 4
Jan 7	Eric J Loumeau Chief Legal Officer	SoldNo plan 4 parts	9,639	$45.56 average	439K	51%	Form 4
Jan 5	Paul F. Lizzul Chief Medical Officer	SoldNo plan	4,219	$43.26	183K	11%	Form 4
Jan 5	Daniel Faga President, CEO	SoldNo plan	15,309	$43.26	662K	3.2%	Form 4
Jan 5	Dennis Mulroy Chief Financial Officer	SoldNo plan	3,363	$43.26	145K	19%	Form 4
Jan 5	Eric J Loumeau Chief Legal Officer	SoldNo plan	2,983	$43.26	129K	18%	Form 4
Dec 23, 2025	J. Anthony Ware Director	SoldNo plan	3,900	$49.58	193K	29%	Form 4
Dec 22, 2025	Paul F. Lizzul Chief Medical Officer	Sold10b5-1 plan	1,500	$50.00	75K	5.3%	Form 4
Dec 22, 2025	Dennis Mulroy Chief Financial Officer	Sold10b5-1 plan	10,000	$50.00	500K	52%	Form 4
Dec 22, 2025	Eric J Loumeau Chief Legal Officer	Sold10b5-1 plan	10,000	$51.00	510K	53%	Form 4
Dec 16, 2025 – Dec 18, 2025	Eric J Loumeau Chief Legal Officer	Sold10b5-1 plan 4 parts	22,641	$45.38 average	$1.03M	72%	Form 4
Dec 16, 2025	Dennis Mulroy Chief Financial Officer	Sold10b5-1 plan 2 parts	15,725	$44.86 average	705K	63%	Form 4
Sep 30, 2025	Eric J Loumeau Chief Legal Officer	Sold10b5-1 plan	8,240	$29.00	239K	48%	Form 4
Aug 8, 2025	Hollings Renton Director	Sold10b5-1 plan 2 parts	10,231	$19.62 average	201K	67%	Form 4
Jul 2, 2025	Hollings Renton Director	Sold10b5-1 plan 2 parts	20,925	$23.57 average	493K	81%	Form 4
Jun 18, 2025	Dennis M Fenton Director	Sold10b5-1 plan	3,015	$23.97	72K	38%	Form 4
Jun 18, 2025	Hollings Renton Director	Sold10b5-1 plan	3,015	$23.97	72K	38%	Form 4
Dec 30, 2024 – Jan 2, 2025	Ecor1 Capital, LLC Large holder	Bought 3 parts	85,098	$12.92 average	$1.1M	1.1%	Form 4
Nov 29, 2024	Hollings Renton Director	Sold10b5-1 plan	10,000	$25.00	250K	84%	Form 4

Oct 110b5-1 plan
Hollings Renton
Director · sold 5,000 at $49.87
249K
31% of stake
Mar 30No plan
John P. Schmid
Director · sold 20,645 at avg $56.11
$1.16M
39% of stake
Mar 27No plan
Daniel Faga
President, CEO · sold 17,679 at avg $61.61
$1.09M
3.4% of stake
Feb 1110b5-1 plan
Eric J Loumeau
Chief Legal Officer · sold 10,000 at $54.00
540K
44% of stake
Jan 15No plan
Magda Marquet
Director · sold 11,000 at avg $48.23
531K
53% of stake
Jan 8No plan
Paul F. Lizzul
Chief Medical Officer · sold 3,650 at $44.71
163K
8.0% of stake
Jan 8No plan
Daniel Faga
President, CEO · sold 14,281 at $44.71
639K
2.9% of stake
Jan 8No plan
Dennis Mulroy
Chief Financial Officer · sold 2,515 at $44.71
112K
10% of stake
Jan 8No plan
Eric J Loumeau
Chief Legal Officer · sold 2,210 at $44.71
99K
15% of stake
Jan 7No plan
Paul F. Lizzul
Chief Medical Officer · sold 2,235 at $45.11
101K
5.7% of stake
Jan 7No plan
Daniel Faga
President, CEO · sold 9,202 at $45.11
415K
1.9% of stake
Jan 7No plan
Dennis Mulroy
Chief Financial Officer · sold 1,908 at $45.11
86K
9.7% of stake
Jan 7No plan
Eric J Loumeau
Chief Legal Officer · sold 9,639 at avg $45.56
439K
51% of stake
Jan 5No plan
Paul F. Lizzul
Chief Medical Officer · sold 4,219 at $43.26
183K
11% of stake
Jan 5No plan
Daniel Faga
President, CEO · sold 15,309 at $43.26
662K
3.2% of stake
Jan 5No plan
Dennis Mulroy
Chief Financial Officer · sold 3,363 at $43.26
145K
19% of stake
Jan 5No plan
Eric J Loumeau
Chief Legal Officer · sold 2,983 at $43.26
129K
18% of stake
Dec 23, 2025No plan
J. Anthony Ware
Director · sold 3,900 at $49.58
193K
29% of stake
Dec 22, 202510b5-1 plan
Paul F. Lizzul
Chief Medical Officer · sold 1,500 at $50.00
75K
5.3% of stake
Dec 22, 202510b5-1 plan
Dennis Mulroy
Chief Financial Officer · sold 10,000 at $50.00
500K
52% of stake
Dec 22, 202510b5-1 plan
Eric J Loumeau
Chief Legal Officer · sold 10,000 at $51.00
510K
53% of stake
Dec 16, 2025 – Dec 18, 202510b5-1 plan
Eric J Loumeau
Chief Legal Officer · sold 22,641 at avg $45.38
$1.03M
72% of stake
Dec 16, 202510b5-1 plan
Dennis Mulroy
Chief Financial Officer · sold 15,725 at avg $44.86
705K
63% of stake
Sep 30, 202510b5-1 plan
Eric J Loumeau
Chief Legal Officer · sold 8,240 at $29.00
239K
48% of stake
Aug 8, 202510b5-1 plan
Hollings Renton
Director · sold 10,231 at avg $19.62
201K
67% of stake
Jul 2, 202510b5-1 plan
Hollings Renton
Director · sold 20,925 at avg $23.57
493K
81% of stake
Jun 18, 202510b5-1 plan
Dennis M Fenton
Director · sold 3,015 at $23.97
72K
38% of stake
Jun 18, 202510b5-1 plan
Hollings Renton
Director · sold 3,015 at $23.97
72K
38% of stake
Dec 30, 2024 – Jan 2, 2025
Ecor1 Capital, LLC
Large holder · bought 85,098 at avg $12.92
$1.1M
1.1% of stake
Nov 29, 202410b5-1 plan
Hollings Renton
Director · sold 10,000 at $25.00
250K
84% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANAB, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANAB

CompareIntrinsic value

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

QUREuniQure N.V.

$23.07-3.35%10

CTMXCytomX Therapeutics Inc.

$2.35+7.80%10

EMMAEmmaus Life Sciences, Inc.

$0.03-17.50%21

CELUCelularity Inc.

$0.81-1.00%0

SCYXScynexis, Inc.

$3.84-2.54%40

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

KROSKeros Therapeutics Inc.

$10.83+0.00%20

Held by ETFs

ANAB is in 54 US ETFs. The largest of them, with ANAB's weight in each:

Spot a number that looks wrong? Check it in ANAB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANAB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.